Ibio"s shares surged after news surfaced it had been working in partnership with Caliber since last year, and its iBioLaunch technology may be used in ZMapp"s production.
In 2013, Ibio entered in a long-term license and collaboration agreement with Caliber, under which the iBioLaunch technology will be utilized to produce biologic drugs in Caliber"s manufacturing facility. The agreement will allow partnership with third parties to produce biotherapeutics and vaccines.
iBioLaunch is the biotech"s proprietary technology that allows production of large-scale commercial quantities of plant-based drugs, including monoclonal antibodies. It is highly likely that Ibio"s technology will be used in the manufacturing of ZMapp, if Caliber is awarded the contract.
Robert Kay, Ibio"s CEO, said Caliber has the capacity to produce up to 100 kilograms of ZMapp annually, which he estimates can produce enough quantity to supply 20,000 patients.
Previously, ZMapp was produced at Reynolds American, Inc."s (RAI) tobacco plant facility in Owensboro. While Reynolds has focused the facility"s full capacity on ZMapp production, only 20 doses are estimated to be produced this year.
Under the agreement with Caliber, Ibio will be entitled to receiving royalty fees, as well as milestone payments subject to the production targets given to Caliber.
ZMapp kann Ebola heilen – zumindest bei Affen. Auch Menschen ließen sich das Serum schon spritzen - und wurden gesund. Die Therapie hätte aber auch tödlich enden können
Nano cap Ibio ([[IBIO]] +83.7%) was up big today on a massive 13.2M shares in response to reports that it may be a player in the government's efforts to ra
Nano cap Ibio (IBIO +83.7%) was up big today on a massive 13.2M shares in response to reports that it may be a player in the government's efforts to ramp up production of Mapp Biopharmaceuticals' Ebola drug ZMapp. Ibio, working with Fraunhofer Center for Molecular Biotechnology, developed a plant-based technology called iBioLaunch that can bring vaccines to market more rapidly. The government is in advanced discussions with Caliber Biotherapeutics on the initiative. Caliber can produce ZMapp in large quantities utilizing its plant-based capabilities and Ibio's iBioLaunch technology which Caliber licensed last year. iBioLaunch causes green plants to produce commercial quantities of targeted human proteins in proper form for use in pharmaceuticals. Under the terms of the license agreement, Ibio will receive license and milestone fees based on the development of product targets selected by Caliber. Ebola-related tickers: (TKMR -4.3%)(BCRX -6.3%)(HEB +11.1%)(INO -0.5%)(NLNK -2%)(OTCQB:GOVX -15.7%)(SRPT -5.4%)(CMRX -2.4%)
rücksetzer wirds bestimmt noch welche geben und das gap sollte ja auch noch geschlossen werden, freitag wurde ja bei knapp über einem euro geschlossen..ist also noch alles offen...
dass es diese woche noch weiter läuft, dann sollten aber mal paar infos seitens der firma kommen damits auch nachhaltig bleibt..wenn nicht gehts vermutlich wieder runter auf 0,60€ wie immer no risk no fun..:)
Der Ausbruch im April / Mai 2011 war vermutlich ein Squeeze, habe da auch schon mal nachgehakt, und eben diese Vermutung als Antwort bekommen. Ja, hier ist sonst noch alles drin, und erst seit Freitag wirklich in starker Aufwärtsbewegung. ZMapp ist neben Tekmira Top-Kandidat für ein Gegenmittel gegen EBOLA, und iBio hat einen Contract mit ZMapp in Aussicht, wenn ich mich nicht irre. Für den derzeitigen Ausbruch gibt es also eine plausible Erklärung.
|
Thread abonnieren
